<-- test --!> Health and Fitness – Page 582 – Best Reviews By Consumers

Health and Fitness

NSCLC: Advances in Treatment

091e9c5e821552a3091e9c5e821552a3custom-fontmodule_custom-font_091e9c5e821552a3.xmlwbmd_pb_templatemodule0144004/01/2021 04:09:160HTML 091e9c5e8221708c091e9c5e8221708ccustom-codemodule_custom-code_091e9c5e8221708c.xmlwbmd_pb_module0144003/10/2022 06:03:290HTML ?xml> Read More

NSCLC: When You Need More Than One Treatment

091e9c5e821552a3091e9c5e821552a3custom-fontmodule_custom-font_091e9c5e821552a3.xmlwbmd_pb_templatemodule0144004/01/2021 04:09:160HTML 091e9c5e8221708c091e9c5e8221708ccustom-codemodule_custom-code_091e9c5e8221708c.xmlwbmd_pb_module0144003/10/2022 06:03:290HTML ?xml> Read More

Having ‘The Talk’ with Your Doctor About Your Late-Stage NSCLC Treatment and Outlook

With late-stage NSCLC, you may want to talk about many things with your doctor. Those might include your treatment options, possible side effects, outcomes, and support systems. Your doctor will tell you what to expect going forward. You also might talk with them about things outside of your medical treatment, like your personal concerns and …

Having ‘The Talk’ with Your Doctor About Your Late-Stage NSCLC Treatment and Outlook Read More »

Bayer to sell men’s health product Nebido™ to Grünenthal

Berlin, July 14, 2022 – Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer’s men’s health product Nebido™ (testosterone undecanoate), for a purchase price totaling up to 500 million Euro. Nebido for the treatment of male hypogonadism (testosterone deficiency) is available in over 80 countries since 2004. In 2021, the …

Bayer to sell men’s health product Nebido™ to Grünenthal Read More »

Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology

Berlin / Boston, June 29, 2022 – Bayer AG announced today the opening of its new Research and Innovation Center at Kendall Square in Boston-Cambridge, Massachusetts (U.S.A.), expanding further the company’s footprint into one of the world’s most innovative pharmaceutical research and development locations. Representing a total $140M USD investment into the area, Bayer’s 62,100-square-foot …

Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology Read More »

Bayer expands Radiology Business into AI Market with Calantic™ Digital Solutions

Berlin, June 28, 2022 – Bayer today announced the launch of Calantic™ Digital Solutions, a new platform delivering access to digital applications, including artificial intelligence (AI) enabled programs for medical imaging. The offering contains tools which aid radiologists and their teams to improve prioritization, lesion detection, quantification, and productivity. By providing access to AI radiology …

Bayer expands Radiology Business into AI Market with Calantic™ Digital Solutions Read More »